View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsFangzhou 향후 성장Future 기준 점검 3/6Fangzhou의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Consumer Retailing 이익 성장21.3%매출 성장률33.1%향후 자기자본이익률25.08%애널리스트 커버리지Low마지막 업데이트12 Jan 2026최근 향후 성장 업데이트공시 • Jan 26Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions.모든 업데이트 보기Recent updates공시 • Mar 09Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026공시 • Feb 02Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing공시 • Jan 27Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing공시 • Jan 26Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions.공시 • Nov 27Fangzhou Inc. and Tencent Healthcare Launch Full-Stack AI Solution for Chronic-Disease ManagementFangzhou Inc. and Tencent Healthcare jointly launched a comprehensive "AI+Chronic Disease Management" solution, marking a major step in the wider deployment of artificial intelligence across China's healthcare sector. The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery. The solution is built on Fangzhou's AI+H2H (H Hospital to Home) ecosystem, a core architecture that embeds proprietary large-model capabilities into chronic-disease workflows. Tencent Cloud, as a leading cloud services provider, offers extensive capabilities in core technological domains including cloud computing, big data, and artificial intelligence. This strategic collaboration will provide a robust technological foundation for the transformation of AI-enhanced chronic disease management. This launch follows Fangzhou's recent AI growth momentum. The October introduction of the Company's "medical report interpretation" feature saw particularly strong adoption, addressing a widespread patient need to better understand complex lab results. Rising engagement levels and session frequency also reflect growing user confidence in AI capabilities. Safety and compliance remain central to Fangzhou's approach. To address the risk of AI hallucinations in sensitive clinical settings, the company has implemented multiple layers of protection, including reinforcement learning with curated knowledge bases, rule-based supervision, and medical-scenario alignment checks. Fangzhou has built its model on Tencent Healthcare's TI platform, leveraging one-stop training, evaluation and deployment pipelines to enable continuous model optimization. Tencent Healthcare's vector database, capable of storing hundreds of billions of domain-specific medical knowledge entries, provides millisecond-level semantic evaluation and improves the accuracy and factuality of RAG-based outputs. For compliance assurance, Tencent Healthcare's AI security WAF supplies fine-grained threat detection and encrypted safeguarding of sensitive medical data, ensuring the solution aligns with regulatory standards for clinical AI. The partnership aligns closely with the National Health Commission's recently issued guidelines on developing safe, standardized "AI + healthcare" applications. Both companies indicated their joint solution will help accelerate digital transformation in chronic care, strengthen medical-service delivery, and support long-term national health goals under the "Healthy China 2030" initiative.공시 • Oct 22Fangzhou Inc. Announces Leveraging Its Proprietary “Xingshi” Large Language ModelFangzhou Inc. announced leveraging its proprietary “XingShi” Large Language Model (“XS LLM”), the company's system integrates AI-enabled tools such as its AI Doctor Assistant, AI Health Manager, and AI Medication Finder to deliver a closed-loop weight management solution. Users can upload their BMI data or health reports to receive tailored recommendations, while patients requiring medication can access 24/7 AI-assisted guidance and follow-up support from licensed medical professionals. Earlier this year, Fangzhou announced strategic partnerships with Novo Nordisk and Innovent Biologics to build AI-powered weight management solutions, representing a significant advance in digital healthcare collaboration. At the symposium, Fangzhou was named as a founding core enterprise of the national “Healthy China: AI + Weight Management Pioneer” initiative, a collaborative effort focused on setting industry standards, fostering innovation, and educating the public on evidence-based weight management. Looking ahead, Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration. By building a smart, standardized, and collaborative framework, the Company aims to transform China’s weight management landscape and contribute to long-term national health priorities.공시 • Sep 15Fangzhou Unveils "XingShi" Large Language Model to Advance AI-Driven Chronic Disease ManagementFangzhou Inc. announced the release of its proprietary "XingShi" Large Language Model ("XS LLM"), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians' available time. XS LLM integrates multimodal capabilities -- image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning -- while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: "AI Knowledge Agent", "AI Guidance Agent", "AI Pre-Consult Agent", "AI Doctor Assistant", and "AI-Electronic Medical Record (EMR) Agent". Together, these agents create a closed-loop service architecture spanning the full lifecycle of chronic disease management. Built as the "core digital brain" of Fangzhou's platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference. This launch reflects Fangzhou's steady AI build-out: from the introduction of its H2H (Hospital-to-Home) digital ecosystem, to the deployment of AI-powered customer service and knowledge base systems, and now to an enterprise-grade medical LLM. With China's "AI+" policy framework accelerating industrial adoption, Fangzhou indicated that XS LLM will anchor future R&D in chronic disease management applications, reinforcing its mission of delivering scalable, precision healthcare.공시 • Aug 15Fangzhou Inc. to Report First Half, 2025 Results on Aug 27, 2025Fangzhou Inc. announced that they will report first half, 2025 results on Aug 27, 2025공시 • Jun 20Fangzhou Inc. Appoints KANG Wei as Member of Nomination Committee, Effective from June 18, 2025The board of directors of Fangzhou Inc. announced that, Ms. KANG Wei, an independent non-executive Director, has been appointed as a member of the nomination committee of the Company, effective from June 18, 2025. Following this appointment, the Nomination Committee now comprises four members, namely Mr. XIE Fangmin (chairman), Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu.공시 • May 28Fangzhou Inc., Annual General Meeting, Jun 19, 2025Fangzhou Inc., Annual General Meeting, Jun 19, 2025, at 09:15 China Standard Time.공시 • Apr 14Fangzhou Presents Ai-Driven Healthcare Ecosystem At Guangzhou Biotech Innovation SalonFangzhou Inc. participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare. Mitigate AI hallucinations: The Company also unveiled its proprietary framework to mitigate AI hallucinations in medical applications, combining a self-developed training platform with a professional medical knowledge base and data sandbox. This approach powers Fangzhou's "AI Agent Matrix," featuring round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation, collectively enhancing care accessibility while reducing operational costs. Blueprint for Vertical AI Leadership: Moving forward, Fangzhou will intensify its focus on the vertical field of AI + Healthcare, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. The Company will seize opportunities like this panel to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare. AI-Powered Growth Strategy: Fangzhou's growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen the Company's technological leadership, and fast-track the market adoption of its innovations — all with the goal of delivering superior care experiences and enhanced solutions for patients and users.이익 및 매출 성장 예측SHSC:6086 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20276,754N/AN/AN/A112/31/20264,509N/AN/AN/A212/31/20253,349N/AN/AN/A26/30/20252,878-242024N/A3/31/20252,793-4391822N/A12/31/20242,707-8551620N/A9/30/20242,587-8581721N/A6/30/20242,466-8621823N/A3/31/20242,450-5291723N/A12/31/20232,434-1971722N/A12/31/20222,204-383-55-50N/A12/31/20211,759-304-209-204N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 6086 의 예상 수익 증가율이 절약률(2.9%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: 6086 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: 6086 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: 6086 의 수익(연간 33.1%)이 Hong Kong 시장(연간 8.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 6086 의 수익(연간 33.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 6086의 자본 수익률은 3년 후 25.1%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YConsumer-retailing 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/03/10 19:22종가2026/03/06 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Fangzhou Inc.는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ruili BianCitigroup IncChujie SunGelonghui Research
공시 • Jan 26Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions.
공시 • Mar 09Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026
공시 • Feb 02Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing
공시 • Jan 27Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing
공시 • Jan 26Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions.
공시 • Nov 27Fangzhou Inc. and Tencent Healthcare Launch Full-Stack AI Solution for Chronic-Disease ManagementFangzhou Inc. and Tencent Healthcare jointly launched a comprehensive "AI+Chronic Disease Management" solution, marking a major step in the wider deployment of artificial intelligence across China's healthcare sector. The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery. The solution is built on Fangzhou's AI+H2H (H Hospital to Home) ecosystem, a core architecture that embeds proprietary large-model capabilities into chronic-disease workflows. Tencent Cloud, as a leading cloud services provider, offers extensive capabilities in core technological domains including cloud computing, big data, and artificial intelligence. This strategic collaboration will provide a robust technological foundation for the transformation of AI-enhanced chronic disease management. This launch follows Fangzhou's recent AI growth momentum. The October introduction of the Company's "medical report interpretation" feature saw particularly strong adoption, addressing a widespread patient need to better understand complex lab results. Rising engagement levels and session frequency also reflect growing user confidence in AI capabilities. Safety and compliance remain central to Fangzhou's approach. To address the risk of AI hallucinations in sensitive clinical settings, the company has implemented multiple layers of protection, including reinforcement learning with curated knowledge bases, rule-based supervision, and medical-scenario alignment checks. Fangzhou has built its model on Tencent Healthcare's TI platform, leveraging one-stop training, evaluation and deployment pipelines to enable continuous model optimization. Tencent Healthcare's vector database, capable of storing hundreds of billions of domain-specific medical knowledge entries, provides millisecond-level semantic evaluation and improves the accuracy and factuality of RAG-based outputs. For compliance assurance, Tencent Healthcare's AI security WAF supplies fine-grained threat detection and encrypted safeguarding of sensitive medical data, ensuring the solution aligns with regulatory standards for clinical AI. The partnership aligns closely with the National Health Commission's recently issued guidelines on developing safe, standardized "AI + healthcare" applications. Both companies indicated their joint solution will help accelerate digital transformation in chronic care, strengthen medical-service delivery, and support long-term national health goals under the "Healthy China 2030" initiative.
공시 • Oct 22Fangzhou Inc. Announces Leveraging Its Proprietary “Xingshi” Large Language ModelFangzhou Inc. announced leveraging its proprietary “XingShi” Large Language Model (“XS LLM”), the company's system integrates AI-enabled tools such as its AI Doctor Assistant, AI Health Manager, and AI Medication Finder to deliver a closed-loop weight management solution. Users can upload their BMI data or health reports to receive tailored recommendations, while patients requiring medication can access 24/7 AI-assisted guidance and follow-up support from licensed medical professionals. Earlier this year, Fangzhou announced strategic partnerships with Novo Nordisk and Innovent Biologics to build AI-powered weight management solutions, representing a significant advance in digital healthcare collaboration. At the symposium, Fangzhou was named as a founding core enterprise of the national “Healthy China: AI + Weight Management Pioneer” initiative, a collaborative effort focused on setting industry standards, fostering innovation, and educating the public on evidence-based weight management. Looking ahead, Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration. By building a smart, standardized, and collaborative framework, the Company aims to transform China’s weight management landscape and contribute to long-term national health priorities.
공시 • Sep 15Fangzhou Unveils "XingShi" Large Language Model to Advance AI-Driven Chronic Disease ManagementFangzhou Inc. announced the release of its proprietary "XingShi" Large Language Model ("XS LLM"), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians' available time. XS LLM integrates multimodal capabilities -- image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning -- while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: "AI Knowledge Agent", "AI Guidance Agent", "AI Pre-Consult Agent", "AI Doctor Assistant", and "AI-Electronic Medical Record (EMR) Agent". Together, these agents create a closed-loop service architecture spanning the full lifecycle of chronic disease management. Built as the "core digital brain" of Fangzhou's platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference. This launch reflects Fangzhou's steady AI build-out: from the introduction of its H2H (Hospital-to-Home) digital ecosystem, to the deployment of AI-powered customer service and knowledge base systems, and now to an enterprise-grade medical LLM. With China's "AI+" policy framework accelerating industrial adoption, Fangzhou indicated that XS LLM will anchor future R&D in chronic disease management applications, reinforcing its mission of delivering scalable, precision healthcare.
공시 • Aug 15Fangzhou Inc. to Report First Half, 2025 Results on Aug 27, 2025Fangzhou Inc. announced that they will report first half, 2025 results on Aug 27, 2025
공시 • Jun 20Fangzhou Inc. Appoints KANG Wei as Member of Nomination Committee, Effective from June 18, 2025The board of directors of Fangzhou Inc. announced that, Ms. KANG Wei, an independent non-executive Director, has been appointed as a member of the nomination committee of the Company, effective from June 18, 2025. Following this appointment, the Nomination Committee now comprises four members, namely Mr. XIE Fangmin (chairman), Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu.
공시 • May 28Fangzhou Inc., Annual General Meeting, Jun 19, 2025Fangzhou Inc., Annual General Meeting, Jun 19, 2025, at 09:15 China Standard Time.
공시 • Apr 14Fangzhou Presents Ai-Driven Healthcare Ecosystem At Guangzhou Biotech Innovation SalonFangzhou Inc. participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare. Mitigate AI hallucinations: The Company also unveiled its proprietary framework to mitigate AI hallucinations in medical applications, combining a self-developed training platform with a professional medical knowledge base and data sandbox. This approach powers Fangzhou's "AI Agent Matrix," featuring round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation, collectively enhancing care accessibility while reducing operational costs. Blueprint for Vertical AI Leadership: Moving forward, Fangzhou will intensify its focus on the vertical field of AI + Healthcare, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. The Company will seize opportunities like this panel to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare. AI-Powered Growth Strategy: Fangzhou's growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen the Company's technological leadership, and fast-track the market adoption of its innovations — all with the goal of delivering superior care experiences and enhanced solutions for patients and users.